NCT03450772Unknown3 期
Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- Abbott
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Coefficient of fat absorption
研究概览
简要总结
This will be an open-label, randomized, multicenter, cross-over study in 60 subjects with PEI delivering data of 60 subjects for Pancreatin Enteric-Coated Capsules 25000 and of 60 subjects for Pancreatin Enteric-Coated Capsules 10000. The study will be conducted in up to 10 sites in China.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Subjects ≥ 18 years
- •A) Chronic pancreatitis must be documented in the medical file by at least one of the following methods:
- •Imaging techniques (ultrasound, CT, MRI, or endoscopic ultrasound)
- •ERCP (endoscopic retrograde cholangiopancreatography)
- •Plain film of the abdomen with pancreatic calcification or
- •B) Partial or total pancreatectomy ≥ 30 days prior to enrollment and without current postsurgery complications
- •PEI proven by human fecal elastase ≤ 100 µg/g stool (during the screening period)
- •Subjects without Creon (Pancreatin Enteric Coated Minimicrospheres) intake in the past three months
- •Females of child-bearing potential should agree to continue using a medically acceptable method of birth control throughout the study and for 30 days immediately after the last dose of study drug. Medically acceptable methods of birth control include bilateral tubal ligation or the use of either a contraceptive implant, a contraceptive injection (e.g. Depo-Provera™), an intrauterine device, or an oral contraceptive taken within the past three months where the subject agrees to continue using during the study or to adopt another birth control method, or a double-barrier method which consists of a combination of any two of the following: diaphragm, cervical cap, condom, or spermicide
排除标准
- •Subjects with a history of fibrosing colonopathy
- •Solid organ transplant
- •Surgery affecting the stomach or bowel, except pancreatectomy or appendectomy
- •Surgery affecting the stomach or bowel, except pancreatectomy or appendectomy
- •Subjects with recurrent malignant tumors of any kind
- •Use of an immunosuppressive drug or chemotherapy
- •Acute phase of pancreatitis
- •Acute phase of pancreatitis
- •Subjects who are not able or willing to ingest 90g fat/day (± 10 g fat/day) during the cross-over periods or are not willing to collect complete stools during the demarcation period.
- •Subjects in an instable condition after pancreatic surgery (Karnofsky index < 70)
- •Known infection with HIV
- •Pregnancy or lactation
- •Current excessive alcohol intake or drug abuse
- •Investigational drug intake within prior 30 days
- •Known allergy against pancreatin of porcine origin or to any of the excipients of Pancreatin Enteric-Coated Capsules
- •Suspected non-compliance or non-cooperation
- •Celiac disease, Crohn´s disease
- •Ileus or acute abdomen in the medical history
- •Mental disability or any other lack of fitness, in the investigator's opinion, to preclude subject's participation in or to complete the study
- •Any acute or chronic disease (i.e infectious diseases) which may limit the hospitalization, dietary adherence or stool collection or completion of the study procedures
研究组 & 干预措施
Creon® 25000 then Creon® 10000
Experimental
Pancreatic enzyme
干预措施: Creon® 25000 (Drug)
Creon® 10000 then Creon® 25000
Active Comparator
Pancreatic enzyme
干预措施: Creon® 10000 (Drug)
结局指标
主要结局
Coefficient of fat absorption
时间窗: 5 days
次要结局
- stool weight(5 days)
- Clinical symptomatology(5 days and 24 weeks)
- fat intake - fat excretion/fat intake x 100(5 days)
- Subject's acceptance of treatment and preference(5 days and 24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)Type 2 DiabetesNCT01541956Novartis Pharmaceuticals3,091
已完成
4 期
Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and IrbesartanType 2 Diabetic NephropathyNCT03147677The Third Xiangya Hospital of Central South University60
尚未招募
4 期
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral MetastasisBreast Cancer Stage IVNCT05860907Fudan University384
已完成
3 期
Study of a New Medical Device in Gel Formulation Versus Calgel® for the Topical Treatment of Teething in InfantsPain TeethNCT02931357Ricerfarma S.r.l54
已完成
4 期
A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 SubjectsCovid19NCT05004753Mateon Therapeutics120